Evidence map›Paper›PMID 33615119›Full record

ArticleDigital biomarkers

The Detection of Vancomycin in Sweat: A Next-Generation Digital Surrogate Marker for Antibiotic Tissue Penetration: A Pilot Study.

Noé Brasier, Andreas Widmer, Michael Osthoff, Markus Mutke, Fiorangelo De Ieso, Pascale Brasier-Lutz, Kitty Brown, Linxing Yao, Corey D Broeckling, Jessica Prenni and 1 more

Open access · goldAbstract read
In one paragraph

Article in Digital biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Noé BrasierCMIO Research Group, Department of Digitalization and ICT, University Hospital Basel, Basel, Switzerland.
Andreas WidmerDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Michael OsthoffDivision of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Markus MutkeCMIO Research Group, Department of Digitalization and ICT, University Hospital Basel, Basel, Switzerland.
Fiorangelo De IesoCMIO Research Group, Department of Digitalization and ICT, University Hospital Basel, Basel, Switzerland.
Pascale Brasier-LutzDepartment of Gynaecology, Kantonsspital Luzern, Standort Wolhusen, Wolhusen, Switzerland.
Kitty BrownAnalytical Resources Core, Bioanalysis and Omics Center, Colorado State University, Fort Collins, Colorado, USA.
Linxing YaoAnalytical Resources Core, Bioanalysis and Omics Center, Colorado State University, Fort Collins, Colorado, USA.
Corey D BroecklingAnalytical Resources Core, Bioanalysis and Omics Center, Colorado State University, Fort Collins, Colorado, USA.
Jessica PrenniDepartment of Horticulture and Landscape, Colorado State University, Fort Collins, Colorado, USA.
Jens EcksteinCMIO Research Group, Department of Digitalization and ICT, University Hospital Basel, Basel, Switzerland.
University Hospital of Basel · CHColorado State University · USLuzerner Kantonsspital · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAssuring adequate antibiotic tissue concentrations at the point of infection, especially in skin and soft tissue infections, is pivotal for an effective treatment and cure. Despite the global issue, a reliable AB monitoring test is missing. Inadequate antibiotic treatment leads to the development of antimicrobial resistances and toxic side effects. β-lactam antibiotics were already detected in sweat of patients treated with the respective antibiotics intravenously before. With the emergence of smartphone-based biosensors to analyse sweat on the spot of need, next-generation molecular digital biomarkers will be increasingly available for a non-invasive pharmacotherapy monitoring.

objectiveHere, we investigated if the glycopeptide antibiotic vancomycin is detectable in sweat samples of in-patients treated with intravenous vancomycin.

methodsEccrine sweat samples were collected using the Macroduct Sweat Collector®. Along every sweat sample, a blood sample was taken. Bio-fluid analysis was performed by Ultra-high Pressure Liquid Chromatograph-Tandem Quadrupole Mass Spectrometry coupled with tandem mass spectrometry.

resultsA total of 5 patients were included. Results demonstrate that vancomycin was detected in 5 out of 5 sweat samples. Specifically, vancomycin concentrations ranged from 0.011 to 0.118 mg/L in sweat and from 4.7 to 8.5 mg/L in blood.

conclusionOur results serve as proof-of-concept that vancomycin is detectable in eccrine sweat and may serve as a surrogate marker for antibiotic tissue penetration. A targeted vancomycin treatment is crucial in patients with repetitive need for antibiotics and a variable antibiotic distribution such as in peripheral artery disease to optimize treatment effectiveness. If combined with on-skin smartphone-based biosensors and smartphone applications, the detection of antibiotic concentrations in sweat might enable a first digital, on-spot, lab-independent and non-invasive therapeutic drug monitoring in skin and soft tissue infections.

Indexed as

Antibiotic stewardshipClinical studySkin and soft tissue infectionsSweat analysisVancomycinWearable sensors

Identifiers

PMID33615119
PMCPMC7879282
OpenAlexW3118725881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.